London (GLOBE NEWSWIRE) -- This exciting report shows that the growth rate in the global biologics drugs market has accelerated recently and is now almost 10% year on year. By 2022 this part of the global pharmaceutical market will be worth $350 billion, and 52% of the top 100 pharma products’ sales value will come from biologics as established chemical pharmaceuticals drop off the patent cliff and new breakthrough biologics are approved. All three of the market’s major segments, monoclonal antibodies, therapeutic proteins and vaccines, are growing at close to the overall market rate.
Metabolic disorders are the largest therapeutic treatment area of the global biologics market, followed by cancer, cardiovascular diseases and immunological diseases. North America is the largest regional market for these drugs and also the fastest-growing, though Asia Pacific is growing almost as fast.
The size of the biologics market is driven by the critical nature of the diseases treated, the drugs’ ability to provide effective treatments for conditions that have been effectively untreatable by traditional drugs, their patented status and the marketing power of the major pharmaceutical companies which are involved in their development. The market is influenced by factors such as regional demographics, initiatives by governments supporting the market, technological advances, criticality in the manufacturing process and increasing biosimilar penetration. The number of biosimilars being approved is rising. This is likely to affect the overall growth of the biologics market value by expanding sales, but also by reducing average pricing. Currently, the proportion of biosimilars to biologics sold is low in the EU (1%) and the USA (4%), but higher in Asia Pacific, at almost 13% for India and 19% for Japan.
The Business Research Company’s Global Market Opportunities And Strategies To 2022 are a new type of industry reports that provide a market overview, analysis and forecasts of market size and industry statistics, market growth rates, market trends, market drivers, market restraints, market revenues, market shares and company profiles of the leading competitors for over 25 industries, over 600 market segments and over 750 markets. These draw on 150,000 datasets, which cover 60+ countries. Extensive secondary research is augmented with exclusive insights and quotations from industry leaders obtained through interviews. Market analysis and forecasts are provided by a highly experienced and expert team of analysts and modelers.
© 2018 GlobeNewswire, Inc. All Rights Reserved.